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1. Introduction 1 
 2 
There are often many different options for improving healthcare policy or improving current practice in 3 
healthcare organizations.  The optimal solution among those options, i.e., the solution that best achieves a 4 
defined goal, such as maximizing patient quality-of-life or minimizing patient waiting time for services, may 5 
not be readily apparent.  Constrained optimization methods use mathematical techniques to help efficiently 6 
and systematically identify the best (optimal) of all possible solutions to a problem while considering the 7 
relevant constraints, such as budget limits or staffing capacity.  8 
 9 
Of course, mathematically optimal solutions to all problems are not always feasible; other non-quantifiable 10 
criteria that cannot be accounted for by defined constraints have to be considered.  However, optimization 11 
techniques can still be highly informative to decision makers in providing insights about optimal target 12 
solutions and the magnitude of the loss of benefit or increased costs associated with the ultimate policy 13 
choice.  In healthcare, failing to identify a mathematically superior or optimal solution represents a missed 14 
opportunity to improve economic efficiency in the delivery of care and clinical outcomes for patients.   15 
 16 
The ISPOR Optimization Methods Emerging Good Practices Task Force provided an introduction to 17 
constrained optimization methods to solve important health policy and clinical problems in its first report 18 
(Crown et al., 2017).  The previous report outlined the relationship of constrained optimization methods 19 
relative to traditional health economic modeling and simulation models and identified some of the major 20 
variants of constrained optimization models, such as linear programming, dynamic programming, integer 21 
programming, and stochastic programming.  22 
 23 
In addition, the report graphically illustrated the formulation and solution of a straightforward integer 24 
program to maximize health benefit subject to a budget constraint.  Further, it explained the steps in an 25 
optimization process:  1) structuring the problem, 2) formulating the mathematical model, 3) developing the 26 
model, 4) validating the model, 5) selecting the optimization method, 6) performing the optimization and 27 
conducting sensitivity analysis, 7) reporting results, and 8) using the results for decision-making.   28 
 29 
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The principal objective of this second Optimization Task Force Report is to illustrate the application of 30 
constrained optimization methods in healthcare decision making.  To identify relevant examples, we began 31 
by searching for award-winning health care papers from the Institute for Operations Research and 32 
Management Sciences (INFORMS) and the Association for European Operations Research Societies 33 
(EURO). From these papers, we then selected examples with models relevant for health economic policy or 34 
clinical decision-making. Finally, we endeavored to select papers that collectively illustrated a variety of 35 
different constrained optimization methods. The three papers that received the most votes from the task 36 
force members were selected.   37 
In this report, two of these three papers are compared with the steps in formulating, solving, validating, 38 
reporting, and using optimization models originally published as Table 3 in the first Optimization Emerging 39 
Good Practices Task Force Report (Table 1 in this report.) The first case study illustrates the application of 40 
linear programming to determine the optimal mix of screening and vaccination strategies for the prevention 41 
of cervical cancer (Demarteau et al., 2012).  The second case illustrates application of the Markov Decision 42 
Process to find the optimal strategy for treating Type-2 diabetes patients for hypercholesterolemia using 43 
statins (Denton et al., 2009). Finally, the third paper is used as an education tool. The goal is to describe the 44 
characteristics of a radiation therapy optimization problem and then invite the reader to formulate the 45 
mathematical model for solving it.  This example is interesting because it lends itself to a range of possible 46 
models, including linear, non-linear, and mixed-integer programming formulations.  (Detailed formulations 47 
for each model are provided in Appendix 1.)   48 
Although we are clearly limited in the number of permutations that we can present with these three cases 49 
we hope the reader will develop a sense of the wide range of problem types that can be addressed with 50 
constrained optimization methods, as well as the variety of methods available.   51 
 52 
2. Overview of applications of constrained optimization in health care 53 
Constrained optimization methods are already widely used in healthcare areas such as choosing the 54 
optimal location for new facilities, making the most efficient use of operating room capacity, workforce 55 
planning, etc.  They can also be instrumental in guiding clinical decision-making in actual clinical practice 56 
where health professionals and patients face constraints, such as proximity to treatment centers, health 57 
insurance benefit designs, and the limited availability of health resources.  58 
 59 
Optimization is also beneficial for planning healthcare expenditure.  An obvious example is the resource 60 
allocation problem faced by a planner with a number of investment opportunities, but a fixed budget 61 
inadequate to fund all available opportunities (Stinnett and Paltiel, 1996).  Perhaps the simplest case of this 62 
is where the investment opportunities are incremental to current care, and fall into distinct categories (e.g., 63 
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children’s services, cardiovascular disease, cancer, respiratory disease and mental health) with separate 64 
budgets (as in Airoldi et al., 2014).  In this situation, decisions about investments in different clinical areas 65 
can be made independently of one another. However, more commonly the health care budget needs to be 66 
allocated across different conditions. The problem of choosing the best set of investment opportunities to 67 
fund under a fixed budget constraint in order to meet an objective, such as maximizing total QALYs can be 68 
addressed as an optimization problem (Martello and Toth, 1990). Given a number of eligible interventions 69 
and a fixed budget, optimization can be used to solve resource allocation problems. In fact, the task central 70 
to health economic analysis, of evaluating whether the incremental cost-effectiveness ratio (ICER) of an 71 
intervention is below a critical threshold, can be shown to be related to budget constrained optimization. 72 
According to the theoretical definition, under a strict set of assumptions, the threshold represents the 73 
inverse of the shadow price of the budget constraint – the shadow price is defined as how much the 74 
objective (i.e. QALYs) would increase for a one-unit increase in the constraint (budget).   (Weinstein and 75 
Zeckhauser, 1973; Thokala, et al, 2018).    76 
 77 
Other resource allocation problems may be even more complicated.  There may be significant and complex 78 
interactions between different investments; and there may also be other constraints such as resource 79 
constraints (e.g. staff, beds, etc) (Thokala et al 2015).   For example, consider the case of allocating 80 
resources for the prevention and cure of an infectious disease such as HIV, Hepatitis C, TB, malaria, or 81 
polio (Castillo-Chavez and Feng, 1998, Juusola and Brandeau, 2015).  If the planner invests in vaccination, 82 
there may be fewer cases to treat in the future (and so investment in highly capital-intensive treatment 83 
facilities may be wasted).  On the other hand, vaccination is itself costly, and if the disease has a low 84 
prevalence, it may be more cost-effective to target the treatment (Lee et al., 2015).  For more details on 85 
these complexities see the ISPOR Economic Evaluation of Vaccines Designed to Prevent Infectious 86 
Disease Good Practices Task Force Report  (Mauskopf et al., 2018).  Optimizing investment in such 87 
infectious disease programs is more complicated as  they may involve making multiple runs of a state-of-88 
the-art simulation (Marshall et al., 2015a, Marshall et al., 2015b) of the infectious disease dynamics, to plot 89 
out how the particular patterns of resource allocation perform against the objective (of minimizing the total 90 
number of cases or maximizing the probability of achieving disease eradication). For a review of 91 
mathematical approaches to infectious disease prediction and control, see (Dimitrov and Meyers, 2010). 92 
 93 
In other settings, the critical resource(s) might not be money.  For example, when allocating donated 94 
organs, (e.g., a kidney), not every kidney will be compatible with every donor.  In addition, the medical 95 
condition of the eligible recipients will be different, some will be more urgent than others.  In this case, the 96 
underlying problem can be categorized as a matching problem (Roth and Sotomayor, 1992; Segey et al., 97 
2005).  In matching problems, not everyone will get the best match.  However, the objective with kidney 98 
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allocation is generally to ensure that as few as possible people and kidneys are left unmatched (patients 99 
without kidneys; kidneys without patients) (Bertsimas et al., 2013).   Bertsimas et al., 2013 present a 100 
discussion about how to incorporate fairness in such problems.  Some measures of deservingness, e.g., 101 
time on waiting list, may be incorporated in the objective function.  Nevertheless, some fairness 102 
considerations may also be included as constraints, e.g., at least x % of transplants should go to patients of 103 
a certain blood type. The 2012 Nobel Prize in Economics was awarded to Shapley and Roth, in part for their 104 
work in stable matchings applied to organ donation.   105 
 106 
Other clinical problems where optimization can be applied relate to problems of disease management, e.g., 107 
timing of the initiation of treatment, or the sequence of treatments.  The promise of health gain from 108 
treatment must be balanced against reasons for holding off treatment, which may include cost, undesirable 109 
side-effects, and emergent drug resistance.  It may be the case that there is an optimal stage in the disease 110 
prognosis or point in the patient’s life cycle where the balance shifts from favoring non-intervention to 111 
favoring treatment.  The MDP approach provides an ideal framework (Puterman, 2014) to study such 112 
problems for identifying critical initiation points.  This framework has been used to analyze timing decisions 113 
in diseases as diverse as HIV, diabetes, and breast cancer (Shechter et al., 2008, Denton et al., 2009, 114 
Chhatwal et al., 2010). Optimization methods can be applied to identify the optimal treatment sequences 115 
when a large number of treatments are available--for example, in rheumatoid arthritis (Tosh et al. 2015). 116 
 117 
Finally, constrained optimization methods have also been applied to disease diagnosis (Lee and Wu, 2009; 118 
Liberatore and Nydick, 2008), the development of optimal treatment algorithms (Ehrgott et al., 2008; Lee et 119 
al., 2008), and the optimal design of clinical trials (Bertsimas et al., 2013). Health technology assessment 120 
using tools from constrained optimization methods is also gaining popularity (Thokala et al., 2018). We also 121 
encourage the readers to refer to the first ISPOR Optimization Emerging Good Practices Task Force 122 
Report, which presented a more comprehensive overview of the different applications for which optimization 123 
techniques can be used (Crown et al., 2017). 124 
 125 
3. Steps in an Optimization Process 126 
Table 1 reproduces the steps of the optimization process previously presented in the initial Optimization 127 
Task Force Report. It is reproduced here to reduce the burden on the reader as the two case studies and 128 
the educational example will all be discussed in light of this framework. The primary purpose of Table 1 is to 129 
support the design of optimization studies by prompting the user to report and justify the choices made at 130 
each step of the process. It should be noted that the steps outlined in Table 1 do not need to be conducted 131 
sequentially. In fact, most of the optimization studies involve performing these steps in an iterative manner 132 
to solve the problem. Along with guiding the design of optimization studies, Table 1 can also be used to 133 
ISPOR Application of Constrained Optimization Methods: Report 2 of the ISPOR Optimization Task Force 
DRAFT FOR REVIEW ONLY 
 
 
5 
 
support the critique and quality assessment of published optimization studies. The steps in Table 1 are 134 
described in detail in the text below. 135 
 136 
Table 1. Steps in an Optimization Process 137 
Stage Step Description 
Modeling Problem structuring Specify the objective(s) and constraints, 
identify decision variables and parameters, 
and list and appraise model assumptions 
Mathematical formulation Present the objective function(s) and 
constraints in mathematical notation using 
decision variables and parameters 
Model development Program the model in software to estimate 
the objective function(s) and constraints, 
using decision variables and parameters as 
inputs 
Model validation Ensure the model is appropriate for 
evaluating different combinations of 
decision variables and parameters 
Optimization Select optimization method 
 
Choose an appropriate optimization method 
and algorithm on the basis of characteristics 
of the problem. 
 
Perform 
optimization/sensitivity 
analysis 
Use the optimization algorithm to search for 
the optimal solution and examine the 
performance of the optimal solution for 
reasonable sets of parameters 
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 Report results Report the results of the optimal solution 
and sensitivity analyses 
Decision making 
 
Interpret the optimal solution and use it for 
decision making 
Source: Crown et al. 2017, Table 3, p. 315. 138 
 139 
Problem structuring: The first step is to determine if constrained optimization is an appropriate 140 
methodology to address the problem at hand (Rosenhead, 1996). It involves identifying if there are any 141 
quantifiable constraints and whether a specific goal can be achieved by changing some (decision) variables. 142 
This problem structuring phase should be done in consultation with the key stakeholders and decision 143 
makers to ensure that the optimization problem is appropriately specified. This will ensure that the objective 144 
functions and constraints are appropriate and get their ‘buy-in’ to change the decision variables in order to 145 
achieve an optimal solution. A clear textual description of the decision problem should be reported and 146 
validated with the key stakeholders and decision makers. 147 
 148 
Mathematical formulation: This involves converting the textual description into a mathematical 149 
representation of the optimization problem. Objective function(s) and constraints need to be defined in 150 
analytical form as a function of decision variables and parameters. Note that decision variables are changed 151 
during optimization iterations in order to identify the optimal solution, while parameters remain fixed. The 152 
number and type of decision variables (e.g. continuous or discrete) as well as the parameters need to be 153 
justified. The type of objective function (i.e. single objective or multi-objective, linear or non-linear, stochastic 154 
or deterministic) and the type of estimation (i.e. analytical estimation or via simulation modelling for complex 155 
problems) need to be specified. Similarly, for constraints, the number of constraints and the type of 156 
estimation used for the constrained quantity need to be reported and justified. The sources and the values 157 
of the parameters used to estimate the objective function(s) and constraints also need to be justified. The 158 
mathematical representation of the optimization problem should be reported after validation with the key 159 
stakeholders and decision makers. 160 
 161 
Model development: This involves programming the model in software to estimate the objective function(s) 162 
and constraints, using decision variables and parameters as inputs. It should be noted that in some 163 
instances, the analytical form of the mathematical formulation can be programmed directly i.e. the 164 
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mathematical formulation sufficiently defines the relationships between objective function(s)/constraints and 165 
decision variables/parameters. However, in other instances, a simulation model needs to be developed to 166 
estimate the objective function(s)/constraints. Models should be designed so that the objective function can 167 
be evaluated based upon the full range of possible decision variables (the feasible region or search space). 168 
The model structure and assumptions should be reported and validated with the key stakeholders and 169 
decision makers.  The initial mathematical formulation and model development steps affect the specification 170 
of the particular optimization method to be applied. These steps are closely related and interdependent.  171 
This is one important reason why the steps in optimization do not always have to follow the order described 172 
in Table 1. 173 
 174 
Model validation: Before the optimization is undertaken, the underlying model needs to be verified and 175 
validated, to ensure the robustness of the results for different analyses performed (i.e. the model is 176 
consistent with reality within tolerances). Once the model has been developed to the point where it is 177 
producing estimates, the model code also needs to be checked to ensure the model results are valid. In the 178 
case of models that represent an analytical formulation directly, this is relatively straightforward as this 179 
involves checking the specific model results used as parameters for estimating the objective function and 180 
constraints.  181 
 182 
However, when a simulation model is used to evaluate the objective function, this would necessitate a 183 
combined approach of simulation-optimization (Lin et al., 2013, Fu, 2002) which is a bit more difficult as it 184 
involves checking the model results for all combinations of decision variables.  Meta-modeling techniques 185 
(Barton 1994), i.e., modeling the simulation model outputs as functions of simulation inputs, can circumvent 186 
getting the simulation results for all variables in the parameter space. These topics are beyond the scope of 187 
this report; we suggest reviewing Sargent (2009) and Law (2006).   188 
 189 
Modelers are encouraged to validate the model results in different parts of the decision variable space to 190 
have enough confidence that the model used is appropriate for optimization (Eddy et al., 2012; Vemer et al., 191 
2014). This should also involve asking the key stakeholders and decision makers to check the model results 192 
for face validity. 193 
 194 
Select optimization method: The choice of optimization method needs to be justified on the basis of the 195 
type of decision variables (i.e. continuous or discrete), and the type of objective function (i.e. single 196 
objective or multi-objective, linear or non-linear, stochastic or deterministic), and the type of constraints (i.e. 197 
single vs multiple constraints). The optimization algorithm/tool used also needs to be justified on the basis of 198 
the optimization method, as well as the estimation type (i.e. analytical formulation vs simulation 199 
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optimization) and other relevant characteristics of the model (e.g. number of decision variables or 200 
transferability of the problem to other well-known problem types). The methods and tools chosen for 201 
optimization need to be reported and justified. 202 
 203 
Perform optimization/sensitivity analysis: This involves running the optimization model, identifying the 204 
optimal solution, and understanding the impact of alternative parameters on the optimal solution using 205 
sensitivity analyses.  Settings used for the optimization, such as the convergence level required or the 206 
maximum number of iterations, need to be justified. In some problems, searching for the optimal solution 207 
might be computationally feasible, whereas in others, solving time increases to such an extent that the use 208 
of heuristics is justified. 209 
 210 
As with decision modelling, optimization can have stochastic uncertainty in parameters and model structure. 211 
Stochastic optimization (Spall, 2005), robust optimization techniques (Gorissen, Yanıkoğlu, and den Hertog, 212 
2015) and sensitivity analyses can be used to deal with parameter uncertainty.  However, structural 213 
uncertainty needs to be dealt with by thinking about the choices throughout the optimization process. For 214 
example, is a linear program really appropriate?  Are the simplifications and assumptions appropriate and to 215 
what extent is there a risk of a wrong/sub-optimal decision being reached? The choice of decision variables, 216 
parameters, constraints, and model assumptions also need to be structurally evaluated.    217 
 218 
The optimal solution needs to be checked to identify if it is feasible and, if so, sensitivity analyses should be 219 
conducted. The optimization settings and the sensitivity analyses need to be explained to the key 220 
stakeholders/decision makers and reported in detail.  221 
 222 
Report results: This involves specifying the values of the decision variables, objective function and 223 
constraints at the optimal solution, for the base case analyses, as well as the sensitivity analyses. The 224 
optimization results (i.e. optimal solution for the base case and sensitivity analyses) need to be reported and 225 
validated with the key stakeholders/decision makers. Also, the performance of the optimization tool/method 226 
needs to be reported, such as the time taken to identify the optimal solution, number of iterations required, 227 
and the convergence level (if applicable). These results should be reported in a manner that is 228 
understandable and interpretable by relevant stakeholders and decision makers. 229 
 230 
Decision making: The meaning of the optimal solution should be explained to the decision makers.  This 231 
involves converting the mathematical optimal solution into clear, concise plans for implementation.  At this 232 
stage, the choices made at all the stages of modelling (i.e. type of model, data, assumptions) and 233 
optimization (i.e. the design, settings and assumptions) need to be validated to ensure the results of 234 
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optimization problem are plausible and consistent with decision maker objectives.  Also, the possibility of 235 
amending the decision variables to the values specified by the optimization process need to be checked 236 
with the stakeholders to ensure that the implementation is feasible. To reiterate, the results of the 237 
optimization should not be used mechanistically: it is the decision makers that implement the findings, 238 
hence they should be comfortable with the methodology, data, and assumptions involved in the whole 239 
optimization process. 240 
 241 
4. Optimization Case Studies 242 
In this section, we consider two constrained optimization studies and compare their structure to the steps 243 
outlined in Table 1.  The first case study focuses on resource allocation for the prevention/cure of infectious 244 
diseases while the second illustrates the use of constrained optimization to guide optimal treatment 245 
initiation. These cases illustrate different modeling techniques, as well as extensions of the application of 246 
constrained optimization methods beyond the typical realm of scheduling, shipping cost minimization, 247 
maximization of facility capacity, etc.   248 
 249 
Case Study 1. Selecting a Mix of Prevention Strategies Against Cervical Cancer (Demarteau et al., 250 
2012) 251 
Problem Structuring  252 
Cervical cancer is the second most common cancer in women under 35 years old in the UK. The objective 253 
of this study was to identify the optimal mix of primary and secondary prevention strategies for cervical 254 
cancer that achieves maximum reduction in cancer cases under budget and logistic constraints.  The 255 
authors applied the optimization model in two countries with different healthcare organizations, 256 
epidemiology, screening practices, resource settings and treatment costs: one in the UK, and one in Brazil. 257 
They considered two cervical cancer prevention strategies against human papillomavirus (HPV): 258 
 Primary prevention – Because an HPV infection is the most common cause of cervical cancer, HPV 259 
vaccination is a primary prevention strategy. Two HPV vaccines are currently available.  Both 260 
vaccines have an efficacy of approximately 98% against the cervical cancer vaccine HPV types 261 
(HPV 16 and 18), but with a different cross-protection profile against oncogenic non-vaccine HPV-262 
types. The implementation of vaccination varies widely among countries with regard to the strategy 263 
selection (national immunization program or individual based); the logistics (via a separately 264 
established vaccination setting or via primary healthcare); the age group targeted; and the gender 265 
selection (female only or both). 266 
 267 
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 Secondary prevention - Cytology-based screening programs have contributed to a decrease of up to 268 
80% in the incidence and mortality of cervical cancer in countries with a well-established, organized 269 
screening program. However, despite their potential, cytology-based screening programs sometimes 270 
have a limited impact due to factors such as sensitivity of the screening method (ability of the test to 271 
correctly identify those patients with the disease), treatment failure and the level of resources 272 
required for an adequate follow-up of patients. 273 
 274 
Four prevention strategies were evaluated: screening; vaccination; screening plus vaccination; and no 275 
prevention because these were the options available for cervical cancer prevention in the UK and Brazil at 276 
the time of the study. Only cytology-based screening was included in the model, with sensitivity estimates 277 
based on published literature. Different screening interval scenarios were explored, from every year to every 278 
25 years (i.e. women are then screened only twice over their lifetime) with a 1-year increment between each 279 
scenario.   280 
 281 
It was assumed that vaccination is administered at age 12 and induces lifelong protection against HPV. In 282 
total, 52 different strategies were tested for each country. These 52 strategies defined the full range of 283 
possible combinations of vaccination (not available or available) and screening interventions (not available 284 
or available with intervals between screening estimated from 1 year to 25 years in 1-year increments).  The 285 
final scenarios can be listed as follows: (scenario 1: no screening & no vaccine; scenario 2: 1-year 286 
screening interval & no vaccine; scenario 3: 2-year screening & no vaccine; … , scenario 26: 25 year 287 
screening & no vaccine’ scenario 27: no screening & vaccine; scenario 28: 1 year screening & vaccine; 288 
scenario 29: 2 year screening & vaccine ; … , scenario 52: 25-year screening & vaccine). 289 
 290 
Mathematical Formulation  291 
The optimization model used a linear programming formulation consisting of a single linear objective 292 
function and multiple linear constraints.  The model was continuous, allowing fractional values for the 293 
decision variables.  It was static meaning that the problem was solved once at steady state.  Finally, the 294 
model was deterministic which assumed that all the outputs were known and there was no stochastic 295 
variation.  296 
Fifty-two decision variables, 𝑥𝑖, each representing the proportion of the population addressed by each 297 
strategy considered, 𝑖 = 1, 2, … , 52, were used with separate identifiers for strategies involving screening 298 
and strategies involving vaccination in order to deal with screening and vaccination coverage constraints. 299 
Given the aim was to minimize the number of cervical cancer cases, the objective function was represented 300 
as the sum of the cervical cancer cases (at steady state for 100 000 women) for each strategy, 𝐶𝐶𝑖, 301 
multiplied by the proportion of population receiving each strategy, 𝑥𝑖.  302 
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The linear programming formulation for the cervical cancer prevention strategy optimization is given as 303 
min 
 ∑ 𝐶𝐶𝑖𝑥𝑖
52
𝑖=1
 
(1) 
subject to 
∑ 𝑏𝑖𝑥𝑖 ≤ 𝐵
52
𝑖=1
 
(budget constraint) 
(2) 
 0 ≤ 𝑥𝑖 ≤ 1, 𝑓𝑜𝑟 𝑖 = 1,2, … , 52 
(strategy coverage bounds) 
(3) 
 
∑ 𝑥𝑖 = 1
52
𝑖=1
 
(complete population distribution) 
(4) 
 
∑ 𝑥𝑖
26
𝑖=2
+ ∑ 𝑥𝑖
52
𝑖=28
≤ 𝐶𝑜𝑣1 
(screening coverage upper bound) 
(5) 
 
 ∑ 𝑥𝑖
52
𝑖=27
≤ 𝐶𝑜𝑣2 
(vaccination coverage upper bound) 
(6) 
 𝑥1 ≤ min (1 − 𝐶𝑜𝑣1, 1 − 𝐶𝑜𝑣2) 
(upper bound on population with no coverage) 
(7) 
 
 𝑥𝑖 ∈ 𝑅, 𝑓𝑜𝑟 𝑖 = 1,2, … , 52 
 
(8) 
 304 
The model has five constraints: budget, strategy coverage, total population, screening and vaccination 305 
coverage limits. The first constraint is to ensure that the sum of the cost for each strategy (at steady state 306 
for 100000 women), 𝑏𝑖,  multiplied by the proportion of the population receiving each strategy, 𝑥𝑖, is less 307 
than the overall budget constraint, 𝐵.  The strategy coverage constraint ensures that the proportion of each 308 
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strategy is between 0 and 1.  The complete population distribution constraint guarantees that all the 52 309 
variables add to 1 (i.e. the sum of the proportion of the population receiving each strategy should reflect the 310 
entire population).  311 
Also, the sum of the proportion of the population receiving strategies including screening should be less 312 
than the externally (e.g. government) imposed screening coverage limit, 𝐶𝑜𝑣1. Similarly, the sum of 313 
proportion of population receiving strategies including vaccination should be less than the externally (e.g., 314 
government) imposed vaccination coverage limit, 𝐶𝑜𝑣2. Note that the parameters 𝐶𝐶𝑖 and 𝑏𝑖 are derived 315 
from the Markov cohort model (see details below) for each strategy 𝑖.  316 
 317 
Model Development: 318 
The mathematical formulation described above used the outputs of a health economic Markov cohort model 319 
(number of cervical cancer cases CCi and total costs bi for each strategy i) as input parameters. The Markov 320 
cohort model describes the population level natural history of cervical cancer for the evaluation of the 321 
clinical and economic consequences of different prevention strategies. The model considers a population of 322 
100,000 women under a given prevention strategy at steady state level. The Markov model consists of 323 
following states: no HPV infection, HPV infection, cervical intraepithelial neoplasia (CIN) stages, cancer, 324 
and death (both cancer and non-cancer related).  325 
 326 
Once patients are infected with HPV, individuals can progress and regress from HPV infection and CIN 327 
stages. Vaccination is assumed to reduce the HPV infection rates, and detection through screening 328 
provides the possibility of the treatment of CIN. Overall vaccine efficacy in the UK and Brazil was calculated 329 
from the country-specific proportions of each HPV type in cervical cancer. Other clinical and cost inputs 330 
were specified of each of these two countries. 331 
The time horizon of the optimization problem was one year, and the health/cost outcomes across the whole 332 
population were derived from the lifetime cohort results from the Markov model.  333 
The model was run with a cohort of women over their lifetime for each one of the 52 scenarios described 334 
above separately for both countries. The results of each scenario were used to estimate the number of 335 
cervical cancer cases and total costs expected over 1 year at steady state for 100 000 women. The 336 
estimated number of cervical cancer cases (𝐶𝐶𝑖) and total costs (𝑏𝑖) of each of the 52 prevention strategies 337 
were then used as input parameters for the optimization model. 338 
 339 
Model validation 340 
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No validation effort was reported, neither for the health economic model nor for the optimization model. 341 
 342 
Select optimization method 343 
Due to relatively small size of the linear programming formulation described above (i.e., a total of 52 344 
decision variables and 57 constraints), a standard primal simplex method was chosen to solve the problem.   345 
 346 
Perform optimization/sensitivity analysis 347 
This optimization problem was programmed in Microsoft Excel as a linear program and solved using the 348 
Solver Add-on (that uses the simplex method) to identify the optimal mix of the 52 cervical cancer 349 
prevention strategies to minimize the expected cervical cancer cases under a fixed budget, as well as 350 
screening and vaccination coverage constraints. The optimization model was solved twice using separate 351 
parameter sets reflecting the settings in UK and Brazil.  352 
The base-case analysis assumed that the maximum screening coverage is the pre-vaccination coverage 353 
rate (65% in the UK and 50% in Brazil), maximum vaccination coverage was set to 80%, and the overall 354 
budget was the pre-vaccination budget allotted to screening and treatment of cervical lesions. No 355 
explanation was given as to why these maximum coverage rates were chosen in the base-case.  356 
Sensitivity analyses were performed to understand the effect of altering the budget or the achievable 357 
screening or vaccination coverages (i.e., the constraints in the model) as well as the duration of vaccine 358 
protection (i.e., one of the parameters in the economic modeling).  The budget constraint was varied from a 359 
20% reduction to a 150% increase over the pre-vaccination levels, while the screening and the vaccination 360 
coverage levels were varied from 0% to 100%. 361 
 362 
Report results  363 
The optimal mix of strategies in the UK was 65% vaccination plus screening with a screening interval of 6 364 
years, and 15% vaccination alone. In Brazil, the optimal mix was 50% vaccination plus screening with a 365 
screening interval of 5 years, and 30% vaccination alone. These optimal mixes of strategies would result in 366 
a reduction of cervical cancer by 41% in the UK and 54% in Brazil from pre-vaccination levels with no 367 
budget increase. It can be easily observed that in both countries, the optimal coverage rates for both 368 
preventive interventions are at the maximum levels permitted in the model. 369 
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In the sensitivity analyses, increasing the budget permits a shortening of the screening interval, but the 370 
effect on the reduction in cervical cancer cases is modest and tends to reach an early plateau. Vaccination 371 
alone (screening coverage set to 0%) could provide a reduction in cervical cancer cases compared with the 372 
pre-vaccination situation of screening alone with a lower budget.  In both countries, the effect of reduced 373 
vaccine efficacy duration (25 years compared with lifetime) still results in a reduction in cervical cancer 374 
compared with the pre-vaccination strategy, but not as much as the base-case analysis. In both countries, a 375 
sharp reduction in the expected number of cervical cancers is seen when the vaccine coverage rate 376 
exceeds the maximum screening coverage rate or when screening coverage rate exceeds the maximum 377 
vaccine coverage rate while maintaining the budget (treatment and prevention) constraint. 378 
 379 
Decision Making  380 
In this case study, within the same budget, results of the optimization program show that it would be 381 
possible to substantially reduce the number of cervical cancer cases by implementing an optimal 382 
combination of HPV vaccination (80% coverage) and screening at pre-vaccination coverage (65% UK, 50% 383 
Brazil) while extending the screening interval to every 6 years in the UK and 5 years in Brazil. 384 
 385 
Optimization models can be used to determine the optimal mix of primary and secondary prevention 386 
strategies minimizing cervical cancer burden under budget and logistic/infrastructure constraints. The key 387 
strength of optimization modeling is its ability to evaluate multiple combinations of different interventions and 388 
identify the mix that provides the maximum expected health benefit (reduction in cervical cancer cases) at 389 
the expected costs within the available budget. In addition, it allows the decision maker to set constraints 390 
reflecting local conditions, such as a limited available budget or limited achievable coverage rates.  391 
 392 
In this paper, the optimization model uses the health economic model outcomes as its input parameters. 393 
Therefore, the validity of the optimization results is based on the validity of the health economic model. 394 
Furthermore, the implementation issues, such as how it will be decided who will receive vaccination, 395 
screening or both, were not discussed. In its current form, the optimization model is used more to 396 
demonstrate the potential value of adding vaccination strategy and to coordinate this addition with the 397 
existing screening practices in the UK and Brazilian health systems. For implementation purposes, a more 398 
advanced optimization model, as well as a more detailed health economic model that takes into additional 399 
considerations and interactions, (e.g. herd protection, resistance dynamics of the virus, transmission to the 400 
others, decreased secondary infections, infertility avoidance, logistic/infrastructure, socio-economic and 401 
equity concerns, etc.), are needed. Lack of these essential considerations in the economic and optimization 402 
models limits the usefulness of the results provided in the paper. 403 
 404 
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Case Study 2: Optimizing statin treatment initiation using MDP (Denton et al., 2009) 405 
 406 
Problem Structuring  407 
Type-2 diabetes (T2D) leads to many chronic outcomes, including stroke, coronary heart disease (CHD), 408 
kidney failure, etc.  This study focuses on the selection of T2D patients for statin therapy of 409 
hypercholesterolemia. The market for statins is significant and remains burdensome to health system costs 410 
despite the availability of generics. Furthermore, there are a number of studies that report overprescribing 411 
(prescribing statins to those patients who only achieve marginal benefit) and under-prescribing (not 412 
prescribing statins to those patients most likely to benefit). Given this debate, Denton and colleagues’ aim 413 
was to identify the optimal time to initiate statin treatment for hypercholesterolemia in T2D patients. 414 
 415 
The problem is set up using an MDP framework.  Traditional health services research methods focus on 416 
efficacy and/or cost-effectiveness at a snapshot in time to inform decisions, while MDP provides an in-depth 417 
modeling and understanding for optimal decisions at multiple time points over a patient’s disease history.  418 
Due to the nature of the modeling, it provides the ability to personalize decisions, as opposed to one-size-419 
fits-all policies and guidelines established for medical decisions.  However, similar to other approaches, 420 
MDPs have assumptions based on data and/or the structure of the model. 421 
 422 
Mathematical Formulation   423 
The model optimizes a cost-reward function over time using a MDP.  We recognize that MDPs are not 424 
commonly associated with constrained optimization because they typically do not have “constraints” in the 425 
same sense that the term is used in the mathematical programming literature (for example, in the previous 426 
case study).  However, the ability of dynamic programming models to identify the optimal solution to the 427 
MDP (i.e., the optimal pattern of statin therapy initiation over time) provides an excellent example of a 428 
clinical use case for constrained optimization as long as one recognizes that constraints in a MDP are 429 
implicitly defined based upon allowable transitions between states and/or available decisions within each 430 
state. The structure of the model reflects shared decision-making by providers and patients over time as a 431 
function of patient age, patient clinical history, and several health states. History is dependent on CHD or 432 
stroke, as well as nine cholesterol levels pertaining to low, medium or high HDL and LDL levels. Patient 433 
information aligning with the data across three major heart studies provides much higher sensitivity to the 434 
proper time to initiate and maintain a statin regimen. The MDP model determines the optimal decision at 435 
each epoch, to maximize the overall rewards 𝑣(𝑠𝑡) while accounting for costs of all future states.  436 
 437 
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Reward function: 𝑀𝑎𝑥 𝑣(𝑠𝑡) = 𝐸
𝑠
→[∑ (𝜆
𝑁𝐷𝑡)𝑟(𝑠𝑡, 𝑎(𝑠𝑡))]
𝑇
𝑡=1 ∀𝑠𝑡 ∈ 𝑆 where t is a time index for discrete 438 
decision epochs, 𝑠𝑡     is an index for states at time period 𝑡 = 1, … , T,  𝑎(𝑠𝑡) is the statin treatment decision 439 
at time 𝑡 = 1, … T,  𝜆𝜖[0,1] discounts the objective function depicting reduced value of rewards in future 440 
years, and 𝑁𝐷 is the number of years in a decision epoch. 441 
 442 
Reward function for each time period: 𝑟(𝑠𝑡, 𝑎(𝑠𝑡)) = 𝑁
𝐷[𝑅(𝑠𝑡) − (𝐶𝐹
𝑆(𝑠𝑡) + 𝐶𝐹
𝐶𝐻𝐷(𝑠𝑡)) − 𝑎(𝑠𝑡)𝐶
𝑆𝑇] −443 
[𝐶𝑆(𝑠𝑡, 𝑎(𝑠𝑡)) + 𝐶
𝐶𝐻𝐷(𝑠𝑡, 𝑎(𝑠𝑡))] where N
D reflects the number of years in a decision epoch, 444 
𝑅(𝑠𝑡) is the monetary value of quality adjusted life years, 𝐶(𝑆t) is the annual cost of statin treatment in period 𝑡,  445 
𝐶𝐹𝑆(𝑠𝑡) is the annual follow up care cost of stroke in period 𝑡, 𝐶𝐹
𝐶𝐻𝐷(𝑠𝑡) is the annual follow up care cost of  446 
CHD event in period 𝑡, CS(sT) is the one time cost of stroke occurring in period t. 447 
 448 
Reward function for final time period: 𝑟(𝑠𝑇 , 𝑎(𝑠𝑇)) = 𝑁
𝐷[𝑅(𝑠𝑇) − (𝐶𝐹
𝑆(𝑠𝑇) + 𝐶𝐹
𝐶𝐻𝐷(𝑠𝑇)) − 𝑎(𝑠𝑇)𝐶
𝑆𝑇] −449 
[𝐶𝑆(𝑠𝑇 , 𝑎(𝑠𝑇)) + 𝐶
𝐶𝐻𝐷(𝑠𝑇 , 𝑎(𝑠𝑇))] + 𝐸[𝑃𝐷𝐻𝑅|𝑠𝑇 , 𝑎(𝑠𝑇)], where 𝐸[𝑃𝐷𝐻𝑅|𝑠𝑇 , 𝑎(𝑠𝑇)] is the post-decision 450 
horizon expected reward. The authors separate the time horizon into a decision horizon and a post-decision 451 
horizon. While the decisions are only made during the decision horizon, the rewards from the post-decision 452 
horizon still need to be included. For instance, while the decision to initiate statin therapy is only until age 453 
80, the rewards of treatment after age 80, need to be included in the model. 454 
 455 
Model Development 456 
The starting age of the patients in the model was 40, and it was assumed that the patients could start statin 457 
treatment at any point between 40 and 80 in 2-year increments. If all these treatment options were modeled 458 
as separate scenarios, as is common in both clinical trials and economic evaluations, the problem would 459 
soon become quite complicated, especially if these treatment options were compared incrementally. 460 
However, using optimization techniques, one can identify a “single” optimal age for initiating statin treatment 461 
that maximizes the ‘reward’ function. The authors interpreted reward in terms of expected net monetary 462 
benefit E(NMB) as a function of quality-adjusted life years (QALYs), Cost and willingness-to-pay threshold 463 
(λ), that is: 464 
 465 
E(NMB) = ΔQALYs*λ – ΔCost    (9) 466 
 467 
Model Validation 468 
The authors do not describe the model validation process, although it is clear from the Acknowledgements 469 
Section of the manuscript that the authors interacted extensively with experts within the clinical system 470 
where the research was conducted, as well as with external reviewers. 471 
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 472 
Select Optimization Method   473 
The problem is set up using a Markov Decision Process (MDP).  The MDP framework is intended for 474 
dynamic streams of decisions (i.e. decisions made over time).  The time horizon and the time steps are 475 
identified as indices for decision epochs.  Each decision in the stream guides the evolution of the system 476 
being modeled (typically the patient’s health in medical applications) and may enable or foreclose further 477 
decisions.  The patient’s health is typically the state, and the decisions or actions are identified.  MDPs can 478 
be considered as a hybrid between a Markov model and a decision tree.   479 
 480 
Just as in Markov models, in an MDP, a patient’s health state changes over time, transitioning from one 481 
discrete state to another according to a specified matrix of probabilities.  However, typically in a Markov 482 
model, the decision maker has a choice between two or more treatment regimens to start the patient on 483 
initially.  By contrast, in an MDP, the decision maker can make a choice about treatment in every time 484 
period.  Thus, it is possible to model at a more granular level.  At each time point, one may decide to start, 485 
stop or switch treatments, for as long as the patient survives.  The constraints may involve the changes in 486 
states and/or the decisions.  The transition from one state to another is characterized probabilistically. 487 
 488 
In this study, the critical decision is when to start statins (starting statins is taken to be a one-time 489 
irreversible decision).  Thus, in each time period from age 40 to death - or age 80 - there is a binary “start” 490 
or “delay” decision.  Much of the complexity of the model is in the modeling of the health states.  There are 491 
324 health states describing various combinations of cholesterol and high-density lipoprotein levels (3 492 
each), as well as stroke and CHD states (6 each).   493 
 494 
Transition probabilities are parameterized based on a proprietary clinical database.  The objective function 495 
is a combination of health sector costs (e.g., cost of treatment transacted between the provider, patient, and 496 
payer) and net monetary benefit, appropriately discounted over time.  The risk of adverse events is 497 
modeled, for comparison through three third-party risk models. 498 
 499 
Different risk-prediction models have estimated probabilities of T2D complications in patients based on 500 
sociodemographic and environmental risk factors. These predictive models can specify the type of 501 
treatment to reduce the risk of comorbidity. The most common validated risk models from several large 502 
studies are the United Kingdom Prospective Diabetes Study (UKPDS), the Framingham Heart Study (U.S.) 503 
and Archimedes, based on data trial results from the Heart Protection Study of 2002.   504 
 505 
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In particular, Denton et al. aimed to identify the optimal decisions for individual patients based on their 506 
attributes including age, gender, total cholesterol and high-density lipoprotein (HDL).  The authors also 507 
performed the analyses using the predictions from each of the three risk models (i.e. UKPDS, Framingham, 508 
and Archimedes) as the choice of the risk model may impact the treatment decision, noting that it was likely 509 
that the predictions from the models could be different. 510 
 511 
Performing optimization 512 
The solution method is based on a backward induction approach starting with the last epoch 𝑇. Knowing the 513 
optimal future actions, the optimal decision at the current epoch can be established using recursive 514 
optimality in the following equation. 515 
Recursive optimality: 𝑣(𝑠𝑡) = 𝜆
𝑁𝐷 max[𝑟(𝑠𝑡, 𝑎(𝑠𝑡)) + ∑ 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎(𝑠𝑡))𝑣(𝑠𝑡+1)]∀𝑠𝑡+1  516 
Where 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎(𝑠𝑡)) is the state transition probability at time 𝑡 given state 𝑠𝑡and action 𝑎(𝑠𝑡)  517 
Decision variable: 𝑎(𝑠𝑡) = {
1 𝑖𝑓 𝑠𝑡𝑎𝑡𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑖𝑠 𝑖𝑛𝑖𝑡𝑖𝑎𝑡𝑒𝑑
0 𝑖𝑓 𝑠𝑡𝑎𝑡𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑖𝑠 𝑑𝑒𝑙𝑎𝑦𝑒𝑑
 518 
𝑤ℎ𝑒𝑟𝑒 𝑖𝑓 𝑎𝑡′ = 1, 𝑡ℎ𝑒𝑛 𝑎(𝑠𝑡) = 1, ∀𝑡 > 𝑡′ 519 
 520 
Sensitivity Analysis 521 
Where uncertainty in the model existed based on recommended statin starting therapy, the results of the 522 
optimization approach were tested for the low, medium and high cost of statins across willingness-to-pay 523 
threshold ranging from $25,000/QALY to $100,000/QALY in $25,000 increments. This additional analysis 524 
provides insight into the value of the model recommendations, and whether the recommendation results 525 
from using a low- or high-value proposition as a starting point. The model was also calibrated to best-526 
available data from that time when statins did not have as much information on long-term effectiveness. 527 
Given that post-market knowledge of statin effectiveness is greater now than in 2009, these results express 528 
uncertainty where greater knowledge now exists. 529 
 530 
Report Results  531 
The model also unifies results across the UKPDS, Framingham, and Archimedes risk models, where there 532 
is noticeable variability in recommended treatment between studies. The Framingham model determines 533 
never to initiate statins for three of the nine metabolic states. The Archimedes risk model does not offer 534 
statin start points for all metabolic states, and predicts statin starting points based on statistical inference 535 
rather than by generalizable samples of patients, making the model prone to statistical error.  In contrast, 536 
the UKPDS and Framingham risk models fit smoothed Weibull distributions across a well-defined population 537 
sample. The UKPDS and the Framingham model, give numerically different, but qualitatively similar optimal 538 
statin start time results. However, using the Archimedes risk model in the optimization did not produce a 539 
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smooth pattern for initiating statin therapy as observed with the UKPDS and Framingham models.  The 540 
authors attribute this to “statistical error” associated with the Archimedes estimates. 541 
 542 
The study demonstrates the value of the MDP framework, providing insight into when to start statin 543 
treatment.  As one would expect, the model generally shows that statins should be started earlier for more 544 
severely ill patients.  Exactly how early depends on the severity of the patient’s condition but also on model 545 
parameters and which risk model is used.  Interestingly, for less severe and elderly patients, from the 546 
results of Figure 2 in the article, it seems that it may not be worthwhile starting statin therapy at all. Women 547 
are in general recommended to start statin treatment later than men.  548 
 549 
Decision Making 550 
The study is an example of how the MDP modeling approach can provide personalized and clinically 551 
relevant recommendations (for patients of type x, start statins at age y) and integrate and compare different 552 
data sources and risk models.  As there are many questions about the right time to start, stop and switch 553 
treatment in medical care, this seems an underused and highly promising framework for economic 554 
evaluation.  555 
 556 
Traditional health services research methods focus on efficacy and/or cost-effectiveness at a snapshot in 557 
time to inform decisions, MDP provides an in-depth modeling and understanding for optimal decisions at 558 
multiple time points over the patient’s disease history.  Due to the nature of the modeling, it provides the 559 
ability to personalize decisions, as opposed to one-size-fits-all policies and guidelines established for 560 
medical decisions.  However, similar to other approaches, MDPs have assumptions based on data and/or 561 
the structure of the model.  Once the results are obtained, sensitivity analyses can be performed (e.g., for 562 
some range of variation in the transition probabilities).  Once satisfied with the solution, translation is in the 563 
form of guidelines and/or decision tools.  Owing to the modeling and computational nature of the MDPs, 564 
they can easily be translated into decision support systems to use in practice. 565 
 566 
This example showed the use of MDP for optimizing the start time of statin therapy.  MDPs can be used for 567 
other similar decision-making problems for breast or prostate cancer screening, the decision for biopsy, 568 
initiating HIV therapy treatment policies, etc.  The underlying theme is focusing on decisions over time, with 569 
decisions at one point affecting future states and decisions operating under constrained resources. The 570 
results of the optimization models can help establish optimal clinical guidelines (Steimle and Denton 2017) 571 
 572 
Educational Case Study: Optimizing the Delivery of Radiation Therapy to Cancer Patients (Shepard 573 
et al., 1999) 574 
ISPOR Application of Constrained Optimization Methods: Report 2 of the ISPOR Optimization Task Force 
DRAFT FOR REVIEW ONLY 
 
 
20 
 
We now challenge the reader to try their hand at formulating alternative models designed to optimize 575 
radiation therapy using the steps outlined in Table 1. The discussion and modeling approach closely follow 576 
the seminal work by Shepard et al. (1999).  A simplified version of the originally published mathematical 577 
notation and formulations are provided in the appendix for the readers to check their formulations. Model 578 
formulation is often the most challenging part of applying constrained optimization methods, and successful 579 
applications typically result from multidisciplinary collaboration, involving domain experts on the subject 580 
matter as well as the modeler. Therefore, one should not feel disappointed if the model specifications do not 581 
exactly match those provided in the appendix.   582 
 583 
There are two main reasons for the selection of radiation treatment planning as the educational case study. 584 
First, the problem statement is relatively simple to express, and so it is a helpful example to showcase 585 
several different constrained optimization models (e.g., linear, nonlinear, mixed integer). Second, while the 586 
problems presented in this educational case study are typically studied by operations researchers and 587 
medical physicists, the parameters defining treatment goals and constraints heavily rely on the health 588 
outcomes research findings comparing the effectiveness of various cancer treatment protocols and 589 
modalities in different patient populations. Therefore, we believe that awareness of these treatment planning 590 
models can lead to new research directions in health outcomes and observational cohort studies.  One such 591 
initiative is the Oncospace (Bowers et al., 2015), the main goal of which is to create a learning health 592 
system that systematically collects relevant clinical data and predicts potential outcomes for specific patient 593 
characteristics and treatment plan parameters (Chen et al., 2016, McNutt et al., 2016). These learning 594 
health systems hold the promise of substantially improved outcomes for all patients.    595 
 596 
Shepard et al. (1999) presented several constrained optimization models for the intensity-modulated 597 
radiation therapy (IMRT) treatment planning problem.  In this setting, a cancerous tumor within a patient’s 598 
body is targeted with several beams of radiation passing through the tumor from different directions since a 599 
single beam of radiation strong enough to control the growth of the tumor would do unacceptable damage to 600 
healthy tissue in its path.  A typical objective function in this setting might be to maximize the portion of the 601 
tumor region receiving a dose of radiation sufficient to prevent further tumor growth while a constraint might 602 
be ensuring that healthy tissue does not receive damaging levels of radiation dose.  The decision variables 603 
might be the angles at which the beams are positioned (Craft, 2007) or the intensity of the subcomponents 604 
of beams, referred to as beamlets (Romeijn et al., 2006). Although the fundamental problem sounds 605 
straightforward in principle, accurately solving it presents substantial conceptual and computational 606 
challenges (Bortfeld, 2006, Sir et al., 2012, Akartunalı et al., 2015). 607 
 608 
Background  609 
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IMRT involves radiation sources (photons or protons) outside the body (Purdy et al., 2012). Several 610 
modeling techniques have been proposed to optimize IMRT considering the complicating factors such as 1) 611 
the underlying physics and biology; 2) conflicting treatment goals; 3) uncertainties caused by daily setup 612 
procedures; 4) organ motion and 5) ensuring that the results and facts garnered in the course of treatment 613 
are efficiently integrated into the treatment plan.   614 
In clinical practice, radiation therapy is delivered over a period of time as a series of small dosages called 615 
“fractions.” Dose delivery in each of these treatment sessions is optimized in order to both increase tumor 616 
control probability (TCP) and decrease damage to the healthy tissue surrounding the tumor by giving it time 617 
to recover (Thames and Hendry, 1987).  Several realistic dose models have been proposed that reflect the 618 
radiobiological effects of fluctuations in dose delivery over fractions (Bortfeld and Paganetti, 2006, Fowler, 619 
1989). These models are used to develop biological indices that can accurately predict the clinical outcome 620 
of radiation treatment, such as equivalent uniform dose (EUD), TCP, and normal tissue complication 621 
probability (NTCP) (Song et al., 2004). 622 
Developing a treatment protocol is complicated - taking multiple considerations into account.  Randomized 623 
control trials and retrospective studies are effective ways of determining the efficacy of various treatment 624 
protocols. Furthermore, while treatment protocols are designed for specific cancer types and patient 625 
populations, each patient has unique characteristics, comorbidities, tumor location and size, and proximity 626 
of tumor region to organs-at-risk (e.g., rectum in the case of prostate cancer) and normal tissue. Therefore, 627 
radiation therapy treatment plans must be optimized to ensure that the treatment protocol requirements are 628 
satisfied for each patient. The remainder of this section will focus on IMRT treatment planning.  Similar 629 
models can be used for other radiation therapy modalities as well.  630 
The steps in the optimization checklist will be followed below. In each step, we will provide necessary 631 
background information first and then ask the reader questions related to important aspects of that step. We 632 
will provide sample answers to some questions to assist the reader with the modeling exercise.  633 
Problem structuring  634 
Decisions in radiation treatment planning involve determining the intensity of modulated beams and the 635 
amount of dose delivered to various points in and around the tumor region. The treatment protocol, 636 
prescribed by a radiation oncologist, specifies treatment objectives and constraints. For example, according 637 
to a prostate cancer randomized control trial (RCT) conducted by Pollack et al. (2002), delivering 78 Grays 638 
of radiation dose to a prostate tumor results in substantial improvement in tumor control.  However, the 639 
higher doses also increase complications in the rectum, which is an organ-at-risk that needs to be protected 640 
from high doses. Using these findings as part of a treatment protocol, consider how you would design the 641 
objective function to ensure that most of the tumor region receives 78 Grays of radiation dose.   642 
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Think about these two possibilities: 643 
1. For every point in the tumor region, you can calculate the difference between the actual dose and 644 
the prescribed target dose, i.e., 78 Grays. You can describe an objective function that minimizes the 645 
largest difference as follows: Minimize the maximum difference between the actual and prescribed 646 
target doses across all points in the tumor region. 647 
2. Suppose that the radiation oncologist is OK with a small difference (e.g., 2 or 3 grays) but wants to 648 
avoid large differences (e.g., 10 Grays) from the target dose in the tumor region. Similar to the 649 
definition above, describe an objective function in such a way that the more the dose difference at a 650 
certain point in the tumor region from the target dose; the more penalty is accrued. Hint: a square of 651 
the dose differences can create the desired effect. 652 
Further, how would you impose constraints on dose delivered to the rectum region to avoid complications? 653 
Again, consider two possibilities: 654 
1. The radiation oncologist wants to provide overall protection by keeping the dose anywhere in the 655 
rectum region below 30 Grays. You can define a constraint to this effect as follows: The dose at any 656 
point in the rectum must be less than 30 Grays. 657 
2. According to the results from the randomized control trial by Pollack et al. (2002), dose escalation 658 
results in better outcomes for prostate cancer patients if the portion of the rectal volume receiving 70 659 
Grays or more dose can be kept below 25%. How do you define a constraint that ensures this?  660 
 661 
 662 
Figure 1: Discrete representation of patient anatomy. Patient anatomy is discretized into voxels, and 663 
treatment beams are discretized into beamlets. 664 
Mathematical formulation 665 
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For IMRT optimization, voxels, which are volume elements on a rectilinear grid in a three-dimensional space 666 
(this is analogous to a pixel in three-dimensional space), are identified in the anatomy of a patient 667 
undergoing radiotherapy (see Error! Reference source not found.). The radiation fields are modulated 668 
using a multi-leaf collimator (MLC) (Alber and Nüsslin, 2001). Therefore, the radiation beams are regarded 669 
as being comprised of many ``beamlets'' (see Error! Reference source not found.). Once voxels and 670 
beamlets are determined, a dosimetrist calculates how much dose a beamlet of unit intensity can deliver to 671 
a voxel.  672 
Parameters:  673 
Given these descriptions, think about what parameters are needed to formulate an optimization model for 674 
IMRT. For example, it may be convenient to introduce notation 𝑉𝑡, 𝑉𝑜, and 𝑉ℎ to denote the set of the tumor, 675 
organs-at-risk (OAR), and healthy tissue voxels, respectively. One parameter is the prescribed target doses 676 
of the tumor voxels: 677 
𝜏𝑖 is the target dose for tumor voxel 𝑖 ∈ 𝑉𝑡. 678 
Now, try to define notation for the following parameters: 679 
 An upper limit on dose delivered to an organ-at-risk voxel. 680 
 The dose delivered to a specific voxel by a specific beamlet with unit intensity. 681 
What other parameters are needed? Compare your parameter definitions with those provided in the 682 
appendix. 683 
Decision Variables: 684 
There are two sets of decision variables: 1) the intensity of each beamlet; 2) the dose delivered to each 685 
voxel.  686 
Introduce notation to define these variables. Compare your variable definitions to those in the appendix. 687 
Objective function and constraints: 688 
How can you combine these parameters and decisions variables to define an objective function and 689 
constraints? (Refer to your definitions from the problem structuring step.)  690 
The specific choice of objective functions and constraints described above will ultimately determine the type 691 
of constrained optimization model. For example, think about whether a simple linear function can be used to 692 
model the first objective of minimizing the largest difference from a target dose. What type of mathematical 693 
function (see the hint provided above) can be used to model an objective function that penalizes larger 694 
differences from the target dose more? Linear or non-linear? 695 
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After attempting to formulate the IMRT optimization problem, compare your formulation with the ones in the 696 
appendix. 697 
Advanced considerations: 698 
If a radiation oncologist is only concerned with limiting the amount of dose delivered to a certain region, you 699 
can simply use a continuous decision variable representing dose delivered to that region and constrain it to 700 
be below the desired threshold. If, however, the radiation oncologist is interested in sparing only a portion of 701 
an organ (i.e., the second constraint possibility described in the problem structuring step), then think about 702 
what additional (possibly binary) variables you need to model this constraint. 703 
Compare your new variable and constraint definitions to the alternative formulations provided in the 704 
appendix. 705 
 706 
Model development  707 
In this step, the treatment planner implements the model formulation using treatment planning software and 708 
specialized optimization solvers. The treatment planner makes various decisions regarding model 709 
parameters and structure. For example, the treatment planner chooses the density and location of the 710 
voxels to provide a good approximation of the regions of interest specified in the treatment protocol. The 711 
number and positions of the beams that will deliver radiation to the patient are also chosen based on the 712 
geometry of the patient’s anatomy and treatment strategy specified in the protocol. Depending on the 713 
location of the tumor, an appropriate radiation physics software needs to be used to calculate the dose 714 
delivered to a voxel from a unit-intensity beamlet. Once all parameters are specified, the model formulation 715 
is populated with actual parameter values and translated into computer code to communicate with an 716 
optimization solver. 717 
Model validation  718 
The treatment planner goes through several steps to ensure that the model accurately represents the 719 
patient’s anatomy and radiation physics.  Robustness of the optimization parameters determined in the 720 
model development step must be verified in the presence of various uncertainties caused by organ motion, 721 
setup uncertainty, and potential structural changes to the patient’s anatomy during the treatment course. 722 
For example, multiple dose deposition matrices may need to be calculated for different scenarios involving 723 
setup errors.  724 
 725 
Select optimization method  726 
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Selection of the optimization method depends on the model structure and various computational 727 
considerations depending on the tumor site. The treatment planner must make a trade-off between the 728 
treatment plan quality and computational time required to obtain it. For example, the mathematical 729 
formulation of a complex case requiring protection of certain portions of several critical organs in the 730 
neighborhood of the tumor region might result in a complex mixed-integer programming model. Solving 731 
such a model to optimality might take multiple hours, making it clinically intractable. In this case, the 732 
treatment planner may be forced to either change the model structure by making certain simplifying 733 
assumptions or keep the original mixed-integer programming model but use a heuristic method (instead of 734 
an exact solution algorithm such a branch-and-bound) to obtain a good (but not necessarily optimal) 735 
solution in a reasonable amount of time. 736 
 737 
Perform optimization/sensitivity analysis 738 
Optimization of radiation therapy is an iterative process. After solving the mathematical formulation, the 739 
treatment planner reports the results to the radiation oncologist, who then considers several trade-offs 740 
between conflicting goals of controlling tumor vs. sparing healthy tissue and critical organs. In each 741 
iteration, the treatment planner makes changes to the model parameters and sometimes to the structure of 742 
the model. For example, if the radiation oncologist wants to “cool down” the rectum in order to avoid 743 
complications, the treatment planner might lower the limit on the dose delivered to the rectum. The changes 744 
made to the model structure may require switching to a different optimization method (compare different 745 
optimization models and their underlying requirements described in the appendix). 746 
The authors of the case study systematically changed various essential parameters, including bounds on 747 
dose delivered to different regions, objective weights associated with different regions, number of beam 748 
angles, and relative size of the protected portion of an organ-at-risk. 749 
Report results  750 
Following the optimization process, the treatment planner presents the solutions to the radiation 751 
oncologists. Typically, multiple solutions, obtained through the iterative optimization process, are reviewed. 752 
The comparisons between these solutions are made using various dose-volume histograms, iso-dose 753 
curves, and dose distribution heat maps (Barrett et al., 2009). The authors of the case study also used 754 
these visualization methods to compare the quality of various treatment plans obtained by different 755 
optimization models.  756 
 757 
Decision making   758 
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After reviewing multiple solutions and considering various trade-offs between conflicting treatment goals 759 
specified by the protocol, the radiation oncologist chooses a treatment plan, which is then delivered in 760 
multiple treatment sessions.  761 
 762 
Discussion 763 
A substantial portion of cancer patients undergoes radiation therapy at some point during the course of their 764 
disease (Miller et al., 2016). Optimization models help to make tradeoffs between conflicting criteria 765 
specified by the treatment protocol and achieve best outcomes for an individual patient.  766 
This last case described various steps in the optimization checklist to formulate and solve an optimization 767 
model for the radiation therapy treatment planning problem. The case also illustrated how a given problem 768 
could be formulated as a linear program, non-linear program, or mixed integer program.  Further details 769 
including the advantages and disadvantages of each approach are explained in the appendix to provide a 770 
learning opportunity for the reader.  771 
 772 
6.  Conclusion 773 
This is the second report by the ISPOR Constrained Optimization Methods Emerging Good Practices Task 774 
Force.  The primary objective is to provide an overview of areas where optimization methods can be applied 775 
and describe three case studies illustrating the application of constrained optimization methods to critical 776 
clinical and health policy questions. The cases illustrate several of the major variants of constrained 777 
optimization methods and demonstrate the potential of these methods in complementing classical economic 778 
evaluation decision-making framework. In the first case study, linear programming methods were used to 779 
identify the optimal mix of HPV vaccination and screening to minimize the number of cervical cancer cases 780 
subject to a budget constraint. Similarly, in the second case study, MDP and dynamic programming were 781 
used to identify the optimal time to initiate statin therapy in type-2 diabetes patients.  The first two case 782 
studies describe the translation of the original problem into its mathematical formulation, its estimation, 783 
interpretation, and use.  In contrast, the third is an educational case that allows the reader to work through 784 
the formulation of a constrained optimization problem using the ISPOR Optimization Good Practice 785 
Guidelines Checklist. 786 
The healthcare sector faces major challenges with regards to appropriate diagnosis and treatment, 787 
allocation of scarce resources, designing policies, etc.  Constrained optimization methods provide an 788 
approach for finding optimal solutions to complex problems in the face of constraints.  As such, they are 789 
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complementary to and build on the health economic models and simulation methods that are widely used to 790 
guide clinical and policy decision making. 791 
Constrained optimization methods can improve the current reimbursement decision-making processes, 792 
which take the budget constraints partially into account. In the constrained optimization framework, budget 793 
constraints can be incorporated explicitly, together with other types of constraints like human resource or 794 
geographical equity constraints. In addition, when there are numerous treatment options available for 795 
treating patients with a specific condition constrained optimization might prove to be an efficient method for 796 
developing treatment protocols or guidelines compared to the classical economic evaluation framework. 797 
In the current healthcare landscape health economic modeling is widely used to make reimbursement 798 
decisions for new technologies (particularly outside the United States).  Constrained optimization methods 799 
can help decision-makers incorporate related considerations beyond the reimbursement decision itself 800 
including the best way to integrate the new technology with the health-care delivery system, as well as in 801 
technology disinvestment decisions. These are becoming crucial as personalized medicine and 802 
performance-based payment concepts become more common. 803 
It is important to recognize that application of constrained optimization methods in healthcare is still an 804 
emerging area and there are some challenges that must be addressed.  Constrained optimization methods 805 
can be limited by data availability and quality, and validating an optimization model can be 806 
challenging. Choosing and applying the appropriate method can be difficult and require specific expertise.  807 
Interpreting results and knowing which solution algorithm is likely to be best requires a level of 808 
methodological understanding and sophistication.   However, despite these challenges, the application of 809 
constrained optimization methods to health care decision making offers substantial potential benefits which 810 
make them a valuable addition to the arsenal of analytic methods at the disposal of the researcher.  811 
Approaching a problem in the context of mathematical optimization forces modelers to identify and quantify 812 
the endpoint that they are trying to accomplish. But most importantly, constrained optimization takes into 813 
account the limits placed on the solution by real-world factors such as budgets, availability of treatments, 814 
staffing capacity, and patient characteristics.  As a result, the identified optimal solution is much more likely 815 
to be feasible to implement. In a disease management problem, by treating patients optimally, we have the 816 
potential to improve population health and enhance the value associated with health care expenditure. For 817 
individual patients, this means providing treatment with the proper therapy faster. For physicians, this can 818 
help provide optimal health outcomes for their patients, enhance the performance of their medical practice, 819 
and offer more efficient health care delivery. The task force hopes that these two reports will encourage 820 
modelers to explore the use of optimization methods and looks forward to seeing more published 821 
optimization applications and the development of further guidelines and resources as the use of these 822 
methods becomes more widespread. 823 
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Appendix: Model formulations for Case 3 826 
In this section, we guide the reader through the formulation process for the optimization of IMRT. 827 
Parameters:  828 
 𝑉𝑡, 𝑉𝑜, and 𝑉ℎ are the set of tumor, organs-at-risk (OAR), and healthy tissue voxels and 𝑉 is the set 829 
of all voxels. 𝑛𝑡, 𝑛𝑜, and 𝑛ℎ are the number of voxels in corresponding regions and 𝑛 is the number 830 
of all voxels. 831 
 𝐵 is the set of beamlets and by 𝑤𝑗 the intensity of beamlet 𝑗 ∈ 𝐵. 𝑚 is the number of all beamlets. 832 
 𝐷 is the 𝑛 × 𝑚 dose deposition matrix, generated by simulating how an X-ray particle deposits 833 
energy as it travels through the body of the patient. 𝐷𝑖𝑗 is an element of 𝐷 representing the dose 834 
delivered to voxel 𝑖 by beamlet 𝑗 when its intensity is set to unit intensity.  835 
 𝜏𝑖 is the target dose for tumor voxel 𝑖 ∈ 𝑉𝑡. 836 
 𝑙𝑡 and 𝑢𝑡 are the lower and upper bounds on dose delivered to tumor voxels, respectively. 837 
 𝑢𝑜 and 𝑢ℎ are the upper bounds on dose delivered to OAR and healthy tissue voxels, respectively. 838 
Decision Variables: 839 
 𝑤𝑗 is the intensity of beamlet 𝑗 ∈ 𝐵. 840 
 𝑑𝑖 is the dose delivered to voxel 𝑖 ∈ 𝑉. 841 
Objective function: 842 
 𝑓(𝑑;  𝜏) is the treatment objective function where 𝑑 is the vector of doses delivered to each voxel and 843 
𝜏 is the vector of ``target'' doses for each voxel, as specified by the treatment protocol. Several forms 844 
of treatment objective functions have been proposed in the literature. As described above, one 845 
possibility is minimizing the maximum deviation from the tumor target dose specified by the 846 
treatment protocol: 847 
𝑓(𝑑; 𝜏) = min
𝑤
max
𝑖∈𝑉𝑡
|𝑑𝑖 − 𝜏𝑖| 848 
Linear Programming Formulation: 849 
The IMRT optimization problem can be formulated as a linear program (LP) with the above objective 850 
function: 851 
Min max
𝑖∈𝑉𝑡
|𝑑𝑖 − 𝜏𝑖| (1) 
subject to 𝑑𝑖 =  ∑ 𝑤𝑗𝐷𝑖𝑗
𝑗∈𝐵
,   ∀𝑖 ∈ 𝑉 (2) 
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 𝑙𝑡 ≤ 𝑑𝑖 ≤ 𝑢𝑡,   ∀𝑖 ∈ 𝑉𝑡 (3) 
 𝑑𝑖 ≤ 𝑢𝑜,   ∀𝑖 ∈ 𝑉𝑜 (4) 
 𝑑𝑖 ≤ 𝑢ℎ ,   ∀𝑖 ∈ 𝑉ℎ (5) 
 ∑ 𝑑𝑖
𝑖∈𝑉𝑜
≤ 𝑛𝑜𝛽 
(6) 
 𝑤𝑗 ≤
𝛼
𝑚
∑ 𝑤𝑘
𝑘∈𝐵
,   ∀𝑗 ∈ 𝐵 (7) 
 𝑤𝑗 ≥ 0,    ∀𝑗 ∈ 𝐵 (8) 
Even though the objective function (1) is nonlinear, it can easily be converted to equivalent linear function 852 
by simple variable transformations. Constraint set (2) defines the relationship between dose delivered to 853 
each voxel and beamlet intensities. Constraint sets (3)-(5) restrict maximum and minimum dose received at 854 
various treatment regions. Constraint (6) limits mean dose delivered to OAR to be lower than a 855 
predetermined constant 𝛽. Constraint set (7) ensures that the ratio between maximum and average beamlet 856 
intensity does not exceed a predetermined constant 𝛼 in order to avoid extremely high dose regions in 857 
patient anatomy. Finally, constraint set (8) ensures beamlet intensities in the optimal solution are positive. 858 
Nonlinear Programming Formulation: 859 
Instead of penalizing the maximum deviation from the target dose, the radiation oncologist may want to 860 
avoid any significant deviations from the target dose. In this case, we can construct an objective function 861 
with a quadratic penalty for deviating from the target dose.   862 
 
𝑓(𝑑; 𝜏) = min
𝑤
𝑟𝑡 ∑(𝑑𝑖 − 𝜏𝑖)
2
𝑖∈𝑉𝑡
+ 𝑟𝑜 ∑(𝑑𝑖 − 𝜏𝑖)
2
𝑖∈𝑉𝑜
+ 𝑟ℎ ∑(𝑑𝑖 − 𝜏𝑖)
2
𝑖∈𝑉ℎ
, 
(9) 
where 𝑟𝑡, 𝑟𝑜, and 𝑟ℎ are weights associated with corresponding regions representing their relative 863 
importance. The target dose for OAR and healthy tissue is typically zero, meaning that any dose delivered 864 
is penalized. These weights are determined through an iterative process between the treatment planner and 865 
radiation oncologist in quest for finding the right trade-off between multiple conflicting treatment criteria 866 
specified by the treatment protocol. A nonlinear programming model can be obtained by replacing objective 867 
function (1) with (9).  868 
Mixed-integer Programming Formulation: 869 
As mentioned above, according to the results from the randomized control trial by (Pollack et al., 2002), 870 
dose escalation results in better outcomes for prostate cancer patients if the portion of the rectal volume 871 
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receiving 70 Grays or more dose can be kept below 25%. These types of requirements in treatment 872 
protocols are referred to as dose-volume constraints representing the willingness of radiation oncologist to 873 
sacrifice a portion of an organ-at-risk to improve tumor control. Dose-volume constraints can be introduced 874 
by defining binary variables that indicate whether the dose to each voxel in the region of interest is above a 875 
certain value (e.g., 𝜆). For example, we can define the binary variable for a dose-volume constraint on an 876 
OAR, which constrains number of voxels in the OAR receiving a dose higher than a specified value, as 877 
follows:  878 
 
𝑥𝑖 = {
1,    if 𝑑𝑖 ≥ 𝜆    
0,     otherwise
,   ∀𝑖 ∈ 𝑉𝑜 
(10) 
The dose-volume constraint can then be formulated as follows 879 
 𝑑𝑖 ≤ 𝑢𝑜 + 𝑀𝑥𝑖,   ∀𝑖 ∈ 𝑉𝑜, (11) 
 ∑ 𝑥𝑖𝑖∈𝑉𝑜 ≤ 𝛿𝑛𝑜,   ∀𝑖 ∈ 𝑉𝑜, (12) 
where 𝛿 is the specified percentage and 𝑀 is an appropriately large number. 880 
The variables defined in (10) are required to be binary, which substantially increases computation time to 881 
find the optimal solution compared to the LP formulation in (1)-(8). 882 
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